AUTHORS
Baokun Gu, Hieu Liem Nguyen, MS2, Akhil Aakunuri, PharmD, MHI3, Noelle Townsend4, Zhengrui Xiao, MD5, Irina Murakhovskaya, MD6
AFFILIATIONS
1 Albert Einstein College of Medicine, Bronx, New York, United States
2 Albert Einstein College of Medicine, Bronx, New York, United States
3 Montefiore Medical Center, Bronx, New York, United States
4 Touro College of Osteopathic Medicine, Middletown, New York, United States
5 Albert Einstein College of Medicine, Bronx, New York, United States, Montefiore Medical Center, Bronx, New York, United States
6 Albert Einstein College of Medicine, Bronx, New York, United States, Albert Einstein College of Medicine, Bronx, New York, United States
ABSTRACT
Introduction: Fatigue is an important patient reported quality of life symptom in patients with autoimmune cytopenias including immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA), and cold agglutinin disease and is reported in the majority of patients. Depression has been reported in most patients with ITP (Cooper et al. American Journal of Hematology 2026;101(8): 1954–1968). Patients with cold agglutinin disease are more likely to have therapy, medications and hospitalization related to depression or anxiety. (Broome et al. PLoS One 2022; 17(12):e0276617.
The goal of this study was to prospectively characterize association between fatigue and emotional burden in patients with autoimmune cytopenias and association with clinical and laboratory factors.
Methods: Consecutive consenting patients > 18 years of age with autoimmune hematologic disorders (ITP, wAIHA, Evan’s Syndrome and thrombotic thrombocytopenic purpura, TTP) presenting to immunohematology clinic from March 2026 – July 2026 were prospectively enrolled in the study. Fatigue was evaluated with Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, depression with Patient Health Questionnaire-9 (PHQ-9), and anxiety with Generalized Anxiety Disorder (GAD)-7 questionnaire. Demographic, clinical and laboratory characteristics, associated conditions, and treatment history at the time of the questionnaire was evaluated by history and chart review. Values for CBC were recorded on the day of the questionnaires completion. Correlation analysis was used to assess the association between FACIT-Fatigue scores and GAD7 and PHQ-9 scores, CBC, LDH, reticulocyte count and number of lines of therapy. All other analyses were descriptive.
Results: Twenty-two patients including 11(50%) ITP, 3 (14%) WAIHA, 3 (14%) Evan’s, 5 (23%) TTP were enrolled in the study. Patients identified as White comprised 17% (4) of the cohort, African American 32% (7), and Hispanic/Latino 32%(7). The mean (SD) age was 57 (16.7) years, and 59% of patients were female. Associated autoimmune conditions were present in 3 patients (one each granulomatosis with polyangiitis, Sjogren syndrome, inflammatory bowel disease), 2 (9%) history of lymphoproliferative disease (one Hodgkin’s disease, one non-Hodgkins’s lymphoma, both in remission), one (4.5%) patient with common variable immune deficiency (CVID), 3 (14%) patients with chronic viral infections (one HIV, 2 HCV). Most patients (91%) received at least two lines of therapy. Mean (SD) number of lines of therapy was 2.3 (1.7). All 5 patients with TTP were in hematologic remission with median (IQR) LDH 182 (172-205). Median (IQR) hemoglobin was 11.6 (10.8-14.4)d/dL in patients with AIHA/Evans (N=8), median (IQR) platelet count was 92 (41-140) × 109/L for the ITP group (N=11).
The mean (SD) FACIT Fatigue, GAD-7 and PHQ-9 scores were 38.5 (8.4), 3.5 (3.26) and 3 (2.4), respectively. Mean FACIT-Fatigue score for general population has been reported as 43.5, with lower scores indicating more severe fatigue. Depression (PHQ-9 score ≥ 5) and anxiety (GAD-7 score ≥ 5) were reported by 5 (23%) and 4 (18%) of patients, respectively. FACIT-Fatigue score was negatively correlated with PHQ-9 score (Pearson’s r = 0.62, n = 22, p = 0.002) and GAD-7 score (Pearson’s r = -0.45, n=22, p = 0.036), as well as LDH (r=-0.6, n = 21, p=0.004). No correlation was seen between FACIT-Fatigue score and hemoglobin, platelet count, absolute reticulocyte count, or number of lines of therapy.
Conclusion: Fatigue is common among patients with immune hematologic disorders and is correlated with presence of mental health symptoms including depression and anxiety. Identification of fatigue and mental health impact in patients with autoimmune hematologic conditions are important and provide a valuable therapeutic target to alleviate disease burden independently of hematologic improvement. LDH may reflect underlying inflammatory response and potentially serve as a biomarker in patients with autoimmune cytopenias.
DISCLOSURES
Baokun Gu: No relevant conflicts of interest to declare.